RPN2 gene confers osteosarcoma cell malignant phenotypes and determines clinical prognosis

Molecular Therapy Nucleic Acids

Volumn 3, Issue 9, 2014, Pages

  Fujiwara, Tomohiro ^a,b,c   Takahashi, Ryou U ^a   Kosaka, Nobuyoshi ^a   Nezu, Yutaka ^a   Kawai, Akira ^b   Ozaki, Toshifumi ^c   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

drug response; metastasis; osteosarcoma; ribophorin II (RPN2); RNA interference

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; MESSENGER RNA; METHOTREXATE; RIBOPHORIN II; SHORT HAIRPIN RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFANT; LUNG METASTASIS; MALE; MOUSE; NEWBORN; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; OSTEOSARCOMA CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 85176826539     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.35     Document Type: Article

References (43)

1. Dean, M, Fojo, T, and Bates, S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
2. Gupta, GP, and Massague, J (2006). Cancer metastasis: building a framework. Cell 127: 679-695.
3. Kuczynski, EA, Sargent, DJ, Grothey, A and Kerbel, RS (2013). Drug rechallenge and treatment beyond progression-implications for drug resistance. Nat Rev Clin Oncol 10: 571-587.
4. Steeg, PS (2006). Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895-904.
5. Steeg, PS and Theodorescu, D (2008). Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5: 206-219.
6. Allison, DC, Carney, SC, Ahlmann, ER, Hendifar, A, Chawla, S, Fedenko, A et al. (2012). A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012: 704872.
7. Bacci, G, Longhi, A, Versari, M, Mercuri, M, Briccoli, A and Picci, P (2006). Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106: 1154-1161.
8. Bacci, G, Rocca, M, Salone, M, Balladelli, A, Ferrari, S, Palmerini, E et al. (2008). High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 98: 415-420.
9. Baldini, N, Scotlandi, K, Barbanti-Bròdano, G, Manara, MC, Maurici, D, Bacci, G et al. (1995). Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380-1385.
10. Bielack, SS, Kempf-Bielack, B, Delling, G, Exner, GU, Flege, S, Helmke, K et al. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790.
11. Bramer, JA, van Linge, JH, Grimer, RJ and Scholten, RJ (2009). Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 35: 1030-1036.
12. Glasser, DB, Lane, JM, Huvos, AG, Marcove, RC and Rosen, G (1992). Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 69: 698-708.
13. Weeden, S, Grimer, RJ, Cannon, SR, Taminiau, AH and Uscinska, BM; European Osteosarcoma Intergroup (2001). The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 37: 39-46.
14. Fujiwara, T, Kawai, A, Yoshida, A, Ozaki, T, and Ochiya, T (2013). Cancer stem cells of sarcoma. In: Thomas, D, Enrico, M, Kurt, SZ (eds). Role of Cancer Stem Cells in Cancer Biology and Therapy. CRC Press: New Hampshire pp. 23-72.
15. Mirabello, L, Troisi, RJ and Savage, SA (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543.
16. Gupta, A, Meswania, J, Pollock, R, Cannon, SR, Briggs, TW, Taylor, S et al. (2006). Noninvasive distal femoral expandable endoprosthesis for limb-salvage surgery in paediatric tumours. J Bone Joint Surg Br 88: 649-654.
17. Kawaguchi, N, Ahmed, AR, Matsumoto, S, Manabe, J, and Matsushita, Y (2004). The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res419: 165-172.
18. Ferguson, WS and Goorin, AM (2001). Current treatment of osteosarcoma. Cancer Invest 19: 292-315.
19. Khanna, C, Wan, X, Bose, S, Cassaday, R, Olomu, O, Mendoza, A et al. (2004). The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10: 182-186.
20. Honma, K, Iwao-Koizumi, K, Takeshita, F, Yamamoto, Y, Yoshida, T, Nishio, K et al. (2008). RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 14: 939-948.
21. Grignani, G, Palmerini, E, Dileo, P, Asaftei, SD, D'Ambrosio, L, Pignochino, Y et al. (2012). A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23: 508-516.
22. Hattinger, CM, Pasello, M, Ferrari, S, Picci, P and Serra, M (2010). Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15: 615-634.
23. Iwao-Koizumi, K, Matoba, R, Ueno, N, Kim, SJ, Ando, A, Miyoshi, Y et al. (2005). Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422-431.
24. Cortes, EP, Holland, JF, Wang, JJ, Sinks, LF, Blom, J, Senn, H et al. (1974). Amputation and adriamycin in primary osteosarcoma. N Engl J Med 291: 998-1000.
25. He, A, Qi, W, Huang, Y, Sun, Y, Shen, Z, Zhao, H et al. (2013). Comparison of pirarubicinbased versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. Int J Clin Oncol 18: 498-505.
26. McTiernan, A and Whelan, JS (2004). A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma. Sarcoma 8: 71-76.
27. Okuno, S, Edmonson, J, Mahoney, M, Buckner, JC, Frytak, S and Galanis, E (2002). Phase II trial of gemcitabine in advanced sarcomas. Cancer 94: 3225-3229.
28. Navid, F, Willert, JR, McCarville, MB, Furman, W, Watkins, A, Roberts, W et al. (2008). Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113: 419-425.
29. Asada, M, Furukawa, K, Segawa, K, Endo, T and Kobata, A (1997). Increased expression of highly branched N-glycans at cell surface is correlated with the malignant phenotypes of mouse tumor cells. Cancer Res 57: 1073-1080.
30. Dennis, JW, Granovsky, M and Warren, CE (1999). Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1473: 21-34.
31. Gu, J, Sato, Y, and Isaji, T (2008). N-glycans regulate integrin ?5?1 functions In: Taniguchi, N, Suzuki, A, Ito, Y, Narimatsu, H, Kawasaki, T, Hase, S (eds). Experimental Glycoscience. Springer: Tokyo. pp. 358-359.
32. Gu, J and Taniguchi, N (2004). Regulation of integrin functions by N-glycans. Glycoconj J 21: 9-15.
33. Guo, HB, Lee, I, Kamar, M, Akiyama, SK and Pierce, M (2002). Aberrant N-glycosylation of beta1 integrin causes reduced alpha5beta1 integrin clustering and stimulates cell migration. Cancer Res 62: 6837-6845.
34. Nabeshima, K, Inoue, T, Shimao, Y and Sameshima, T (2002). Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52: 255-264.
35. Pocheć, E, Lityńska, A, Amoresano, A and Casbarra, A (2003). Glycosylation profile of integrin alpha 3 beta 1 changes with melanoma progression. Biochim Biophys Acta 1643: 113-123.
36. Kawashima, A, Kawahara, E, Tokuda, R and Nakanishi, I (2001). Tumour necrosis factoralpha provokes upregulation of alpha2beta1 and alpha5beta1 integrins, and cell migration in OST osteosarcoma cells. Cell Biol Int 25: 319-329.
37. Tominaga, N, Hagiwara, K, Kosaka, N, Honma, K, Nakagama, H and Ochiya, T (2014). RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy. Mol Cancer 13: 134.
38. Takahashi, RU, Takeshita, F, Honma, K, Ono, M, Kato, K and Ochiya, T (2013). Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3?. Sci Rep 3: 2474.
39. Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
40. Haussecker, D (2012). The Business of RNAi Therapeutics in 2012. Mol Ther Nucleic Acids 1: e8.
41. Ramachandran, PV and Ignacimuthu, S (2013). RNA interference-a silent but an efficient therapeutic tool. Appl Biochem Biotechnol 169: 1774-1789.
42. Luu, HH, Kang, Q, Park, JK, Si, W, Luo, Q, Jiang, W et al. (2005). An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 22: 319-329.
43. Youden, WJ (1950). Index for rating diagnostic tests. Cancer 3: 32-35.